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Abstract. Introduction: Autoinflation is a troublesome complication following penile prosthesis placement that
may be potentiated by prevesical scarring following radical prostatectomy. We evaluated the frequency of auto-
inflation and other complications following penile prosthesis placement in radical prostatectomy patients and
controls as a surrogate to establishing the utility of lockout reservoirs in preventing autoinflation. Methods:
139 prostheses (including 14 with lockout reservoirs) were placed in 132 men (including 35 post-prostatectomy
patients) over a 51/2 year period at our institution. Outcomes assessed include postoperative complications and
the need for revision or replacement of the prosthesis. Multivariable regression analysis was used to determine
the association of patient, device-specific, and perioperative characteristics with these outcomes. Results: There
was no difference in the postoperative complication and re-operation rates between post-prostatectomy patients
and controls (both p > 0.77). The incidence of autoinflation in post-prostatectomy patients and controls was 3%
and 5%, respectively (p > 0.99). Patients with prior prostheses were 3 times as likely to develop a postoperative
complication or require prosthesis revision (p = 0.02). Conclusion: Penile prostheses are well tolerated in post-
prostatectomy patients with comparable outcomes to those men with organic erectile dysfunction. The frequency
of autoinflation does not appear to be increased in post-prostatectomy patients. Initial results with the lockout valve
reservoir in preventing autoinflation are encouraging though additional study is warranted to justify their routine
use.
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Introduction
Since its introduction in 1973 [1], the inflatable penile
prosthesis has taken a prominent role in refractory
erectile dysfunction which is reflective of its high
(80–91%) patient and partner-reported satisfaction
rates [2–4]. However, troublesome prosthetic-related
complications (e.g. subacute infection and autoinfla-
tion) contribute significantly to patient dissatisfaction
[3]. Consequently, manufacturers have attempted to
address these nuisances with novel modifications such
as antibiotic impregnated components and reservoirs
with anti-refluxing (lockout) valves. However, the
utility of such adaptations is unknown.
With a high prevalence (up to 80%) [5] of
erectile dysfunction following radical prostatectomy
for prostate cancer and the marginal response (43%)
[6] of these men to oral medications, placement of
an inflatable penile prosthesis remains a viable option
after pharmacological venues have been exhausted.
However, scarring in the prevesical space after radical
retropubic prostatectomy may potentiate the risk of
autoinflation. Indeed, up to 40% of renal transplant
recipients (who would have similar prevesical scar-
ring) implanted with three-piece devices suffer from
autoinflation [7].
In this context, we evaluated the utility of the
lockout valve reservoir in preventing autoinflation in
post-prostatectomy patients and in those implanted
for other etiologies of erectile dysfunction. To
this end, we assessed the safety and efficacy of
all devices implanted in post-prostatectomy patients
when compared to those implanted without prior pro-
statectomy. Secondarily, we sought to elicit associa-
tions of demographical and device-specific factors





Eligible subjects for this study consisted of 132 men
who had 139 inflatable penile prostheses placed at
our institution between January 1, 1995 and August
15, 2001. Of these patients, 35 men had under-
gone a radical retropubic prostatectomy (n = 33)
or radical cystoprostatectomy (n = 2) for prostate
cancer. One patient in this group had persistent auto-
inflation and 1 had a mechanical malfunction that
mandated replacement of their prostheses. Thus, the
study group is composed of 37 prostheses that were
placed in 35 men. Comparisons were made to a
control group consisting of 97 men without a prior
history of open prostate surgery who had 102 inflat-
able penile prostheses placed. Of these 97 patients,
5 required a second prosthesis – 2 for infection, 1
for corporal erosion, and 2 for mechanical malfunc-
tion. Among these 97 patients, the etiology of erectile
dysfunction was thought to be organic in all cases.
The prevalence of co-morbidities among patients with
organic erectile dysfunction was – diabetes mellitus in
35%, peyronie’s disease in 22%, combined androgen
blockade for prostate cancer in 6%, coronary artery
disease in 12%, and hypertension in 45%.
Technique
Patients were given vancomycin and gentamicin one
hour prior to incision. Minor modifications were made
to a technique that has been previously described
[8–10]. Briefly, a midline penoscrotal or vertical
infrapubic incision was typically made. Two to
3 absorbable sutures were pre-placed along either
side of the corpora incision site, the corpora was
incised and dilated to 14 Fr., measured, and irrigated
with a bacitracin and neomycin containing solution.
Cylinders were always placed with rear-tip extenders
and the corpora were re-approximated with a hori-
zontal mattress closure using the pre-placed sutures.
The reservoir (for 3-piece devices) was placed through
the transversalis fascia via the external inguinal ring,
and the pump placed in a pouch external to the
tunica vaginalis adjacent to the testes. Surgery was
performed under regional or general anesthesia, and
patients remained in the hospital overnight for intra-
venous antibiotics. The Foley catheter was removed
on the morning following surgery, and patients
received a 7-day course of a first generation cephalo-
sporin. Prostheses implanted included the 700 Ultrex,
700 CX(M), Ambicor, and Dynaflex devices from
American Medical Systems, Inc., and the Mentor
Corporation’s Alpha-1 prosthesis with and without
a lockout reservoir. Per surgeon preference, devices
with lockout reservoirs were generally used in post-
prostatectomy patients.
Analysis
Outcomes assessed included postoperative complica-
tion rates and device longevity in post-prostatectomy
and control groups. The frequency of autoinflation
in devices with and without a lockout reservoir was
compared as an additional endpoint. Comparisons
between continuous data were performed using the
two-tailed t-test and those between nominal vari-
ables were made using the chi-square test (or Fisher’s
exact method where appropriate). Prosthesis survival
analysis was assessed using Kaplan-Meier curves and
the log rank (Mantel-Cox) test. Multivariable logistic
regression was utilized to determine the association
of patient, device-specific, and perioperative factors
with the occurrence of a postoperative complication
or the need for additional surgery related to the
implanted device [11]. All analyses were conducted
using Statview 5.0 (SAS Institute, Cary, NC) and all p
< 0.05 were considered significant.
Results
Pre-treatment and follow-up data stratified by
whether or not the patient had undergone a radical
prostatectomy is shown in Table 1. Post-prostatectomy
patients were older (63 vs. 54 years, p = 0.0001) and
had a shorter duration of follow-up (28 vs. 37 months,
p = 0.04) than their counterparts with organic erectile
dysfunction.
Implant specific and postoperative outcomes are
also listed in Table 1. Post-prostatectomy patients
were more likely to have a three-piece device with
a lockout reservoir (27% vs. 4%) and less likely to
have a two-piece (5% vs. 9%) or a one-piece (3% vs.
13%) device placed than those in the control group (p
= 0.0009). We noted no differences in overall post-
operative complication and re-operation rates between
the two groups. Five-year revision-free survival for
the penile implants was similar between prostatectomy
(80%) and control (90%) groups (Mantel-Cox p =
0.26). Overall, 14% of post-prostatectomy patients
and 12% of controls required prosthesis revision (p
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Table 1. Clinical, operative, and postoperative characteristics as a function of previous radical prostatectomy
(± standard deviation)
Variable Post-prostatectomy Control group Entire sample p-value
group (n = 37) (n = 102) (n = 139)
Age 63 ± 8 54 ± 12 56 ± 12 0.0001
Virgin prosthesis (%) 30 (81) 70 (69) 100 (72) 0.20
Time elapsed since implant (months) 28 ± 23 37 ± 25 35 ± 25 0.04
Etiology (%) –
Organic – 102 (100)
Post-prostatectomy 37 (100) –
Device (%) 0.0009
Alpha 1 – 9 (9) 9 (7)
Alpha 1 with lockout reservoir 10 (27) 4 (4) 14 (10)
Ambicor 2 (5) 9 (9) 11 (8)
700 CX 1 (3) 2 (2) 3 (2)
Ultrex 23 (62) 65 (63) 88 (63)
Dynaflex 1 (3) 13 (13) 14 (10)
3-piece prosthesis (%) 34 (92) 80 (78) 114 (82) 0.08
Postoperative complication (%) 7 (19) 18 (18) 25 (18) >0.99
Need to revise prosthesis (%) 3 (8.1) 5 (4.9) 8 (5.8) 0.43
Need for replacement prosthesis (%) 3 (8.1) 8 (7.8) 11 (7.9) >0.99
Overall need for re-operation (%) 5 (14) 12 (12) 17 (12) 0.77
= 0.77) at a mean follow-up of 28 and 37 months,
respectfully.
Twenty-five patients developed a postoperative
complication (Table 2). Of these, 5 patients had
2 complications thereby comprising a total of 30
complications following penile prosthesis surgery. We
noted no difference in the frequency of any single
postoperative complication in the post-prostatectomy
and control groups (all p > 0.19). Specifically, only
1 (3%) post-prostatectomy patient and 5 (5%) patients
in the control group had persistent autoinflation after
prosthesis implantation (p > 0.99). Of these patients,
only one (a post-prostatectomy patient) opted for
replacement of his prosthesis. This patient’s device
was removed and replaced with the Alpha-1 with
lockout reservoir and has been free of autoinflation
since. Among 3-piece devices implanted, only 4 (5%)
Ultrex and 2 (22%) Alpha-1 autoinflated compared
to no Alpha-1 device with a lockout reservoir (p =
0.10). Among only post-prostatectomy patients, only 1
patient with an Ultrex implant developed autoinflation
compared to no patients with lockout reservoirs (p >
0.99).
Multivariate logistic regression analysis was per-
formed to determine associations of pre-treatment,
device-specific, and perioperative factors with the
development of a postoperative complication or the
need for any subsequent operation because of penile
prosthesis implantation. Patients with prior prostheses
were 3 times as likely to develop a postopera-
tive complication as those who had never had a
penile prosthesis (31% vs. 13%, p = 0.02). Other
factors – including age, surgeon experience, type of
device implanted, etiology of erectile dysfunction,
and comorbidities – were not associated with post-
operative morbidity (each partial correlation R = 0).
Similarly, the only factor associated with the need for
any additional procedure after prosthesis implantation
was having a prior implant (odds ratio 3.4, p = 0.02).
Comment
Autoinflation remains a troublesome complication of
inflatable penile prosthesis surgery with an incidence
of 2 to 4% in 3 piece implants [7, 12]. Correct place-
ment of the reservoir into an adequately dissected
prevesical space may minimize the risk of its occur-
rence [13]. However, autoinflation appears to be
more problematic in patients who have had previous
extraperitoneal surgery – the standard location for
reservoir placement. Cuellar and Sklar [7] noted
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Table 2. Postoperative complications in inflatable penile prostheses
Complication Post-prostatectomy Control group Entire sample p-value
group (n = 37) (n = 102) (n = 139)
Erosion (%) 1 (3) 3 (3) 4 (3) >0.99
Infection (%) 1 (3) 4 (4) 5 (4) >0.99
High-riding pump (%) 3 (8) 3 (3) 6 (4) 0.19
Mechanical malfunction (%) 1 (3) 5 (5) 6 (4) >0.99
Persistent pain (%) 1 (3) 1 (1) 2 (1) 0.46
Hematoma (%) 1 (3) – 1 (0.7) 0.27
Autoinflation (%) 1 (3) 5 (5) 6 (4) >0.99
an overall autoinflation rate of 9% in renal trans-
plant patients compared to only 4% in non-transplant
patients. Even more striking was the 40% incidence of
autoinflation in transplant recipients implanted with 3
piece devices compared to 4% in the non-transplant
population [7]. These findings are suggestive that
patients with prior extraperitoneal surgery are pre-
disposed to autoinflation after 3 piece prosthesis
placement.
To address the problem of autoinflation, investi-
gators have proposed overfilling the reservoir to
enlarge the prevesical space [14] or reducing reservoir
volume [15]. To a similar end, the Mentor Corpora-
tion has developed an optional reservoir that contains
an anti-refluxing or lockout valve that may prevent
undesired egress of fluid from the reservoir to the
cylinders.
In this study, none of the 14 patients implanted
with a lockout valve reservoir have developed auto-
inflation – including 10 placed in post-prostatectomy
patients and 4 placed in patients with organic erectile
dysfunction. In contradistinction to the finding of
higher autoinflation rates in patients with previous
extraperitoneal surgery [7], we found that autoinflation
occurred in only 1 (3%) post-prostatectomy patient
compared to 5 (5%) patients with no prior extraperi-
toneal surgery (p > 0.99). Despite the theoretical
benefits that the lockout reservoir may confer, we
noted no improvement in the autoinflation rates in
these devices when compared to others with standard
reservoirs (0% vs. 4%, p > 0.99). However, this may
be reflective of the low incidence of autoinflation in
our study (overall 4%) and our limited experience
with the device given its relative novelty. Nonetheless,
the absence of autoinflation in patients with a lockout
reservoir is promising, and a statistically significant
benefit may be realized as more of these devices are
implanted.
A secondary endpoint of this study was to
evaluate outcomes of inflatable prostheses after radical
prostatectomy when compared to those implanted for
other reasons. One prior study has addressed these
issues specifically in prostate cancer patients who
received external beam radiation therapy. The authors
reported a 6% revision rate and concluded that place-
ment of penile prostheses is safe in post-radiotherapy
patients with minimal intraoperative and postopera-
tive morbidity [16]. In our contemporary series, we
demonstrated similar findings of low morbidity and
need for re-operation in post-prostatectomy patients
when compared to those with implants for organic
erectile dysfunction. Revision-free survival (Mantel-
Cox p = 0.29) and postoperative complication rates
(Table 2) of the post-prostatectomy and control
groups were similar. The validity of these findings
is augmented by the consistency of the complica-
tion rate of our control group with that of a large
multi-institutional study [12].
The final objective of this study was to elicit demo-
graphic and device-specific characteristics associated
with the development of a postoperative complication
or need for surgical revision. Our study population,
which is enriched with post-prostatectomy patients
(27%), provided an excellent setting to assess the asso-
ciation of radical prostatectomy with these outcomes.
However, we noted that only patients with prior penile
implants were more likely to develop a postoperative
complication following prosthesis placement (31%
vs. 13%, p = 0.02). Multivariate logistic regression
analysis confirmed that previous prosthesis placement
was independently associated with higher postopera-
tive complication and revision rates.
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The principle limitations of this study were its lack
of randomization and the small population implanted
with a lockout reservoir (albeit a function of the
novelty of the device within the marketplace). The
problem in assessing the utility of this device is further
augmented by the infrequent occurrence of autoinfla-
tion thereby making a single institutional trial ineffi-
cient. These limitations notwithstanding, this study
serves as a basis for a large, multi-institutional trial to
effectively establish the value of these reservoirs and
other novel modifications to penile prostheses prior to
routine use.
Conclusions
Patients undergoing prosthesis replacement surgery
are at 3-fold increase risk for postoperative complica-
tions and need for surgical revision. Conversely,
post-prostatectomy patients do not appear to be at
higher risk for autoinflation and other complications of
penile prosthesis surgery when compared to controls.
Consequently, the lockout valve reservoir should be
implanted in the context of clinical trials attempting
to establish their utility in a rigorous fashion and
justify their expense. This notwithstanding, the initial
outcomes with the lockout reservoir are promising
with a 0% autoinflation rate. However, larger trials are
necessary to adequately assess the implications of this
and other prosthetic modifications.
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